Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. - Wikidata - wikimedia - TriplyDB

Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines.

Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines.

http://www.wikidata.org/entity/Q35595076

about

Sulfasalazine for ankylosing spondylitis Microparticles as controlled drug delivery carrier for the treatment of ulcerative colitis: A brief review Mesalamine in the treatment and maintenance of remission of ulcerative colitis Tolerance of 4-aminosalicylic acid enemas in patients with inflammatory bowel disease and 5-aminosalicylic-induced acute pancreatitis Discrepancies between population-based data and adverse reaction reports in assessing drugs as causes of acute pancreatitis.Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events Comparison of the effect of mesalazine and sulfasalazine on laboratory parameters: a retrospective observational study.Extraintestinal manifestations and complications in inflammatory bowel diseases.Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?Medical management of Crohn's disease.Inflammatory bowel diseases: Current problems and future tasks.Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis.European evidence based consensus on the diagnosis and management of Crohn's disease: current management.Nutritional supplementation and dietary restriction in the resolution of enthesitis-related arthritis.Five-aminosalicylic Acid: an update for the reappraisal of an old drug Management of arthropathy in inflammatory bowel diseases.Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow.Current therapy of ulcerative colitis in children.Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.Ulcerative colitis: no rise in mortality in a European-wide population based cohort 10 years after diagnosis.Guidelines for the management of inflammatory bowel disease in adults.Polypharmacy and Crohn's disease.Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine.The role of mesalamine in the treatment of ulcerative colitis.5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review.The risks and the benefits of mesalazine as a treatment for ulcerative colitis.Chest pain in a 12-year-old girl with ulcerative colitis after therapy with mesalazine Acute respiratory failure secondary to mesalamine-induced interstitial pneumonitis.Individually administered or co-prescribed thiopurines and mesalamines for inflammatory bowel disease.Renal effects of long-term treatment with 5-aminosalicylic acid Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver.Balsalazide in treating colonic diseases.Colon-specific prodrugs of 4-aminosalicylic acid for inflammatory bowel disease.Efficacy and safety of drugs for ulcerative colitis.Renal manifestations and complications of inflammatory bowel disease.Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity.Treatment of inflammatory bowel disease (IBD) in dogs and cats.Extended-release mesalamine granules for ulcerative colitis.Conventional drug therapy for inflammatory bowel disease.Mesalizine-Induced Acute Pancreatitis and Interstitial Pneumonitis in a Patient with Ulcerative Colitis.

P2860

Q24244129-B0BB86C3-37C7-4514-BD92-1A994D6D9D29 Q26743907-529FA535-7CD4-482E-8CA3-DED0D098EF1C Q26865546-D110B05D-42AA-4E43-9E5D-D62472246E01 Q28275376-8429D81E-1671-4A6F-8716-EA6150971B03 Q30780380-877B93BA-7DF4-4630-B983-39F79E9F0857 Q33327765-B9FD5030-36FE-4909-8D0B-F26267D1AD40 Q33401006-77A790C8-0D29-429F-B405-807D5CE07C4D Q33866998-8EC15E3C-59CF-40FF-90B7-33519BC45EE2 Q33868970-EB788DBD-852C-4289-A2E7-A9526EBBB486 Q34046139-B95D62D6-B46A-467B-89CC-946D6BB7D7FE Q34047672-314439C3-B571-402B-8B07-22F36836CFE7 Q34273329-24E3F8F2-D848-4832-AFDA-13908ED07C52 Q34564902-56081FB2-A4E3-4789-B187-7FD3A0DD1FF5 Q34904542-6C608000-0787-48D6-AFB1-8B8305B93228 Q35061210-51CCC0D3-6DC7-4236-8B21-80455DC6AE67 Q35091366-48DDBDEE-C72F-4341-B80E-59C0034A66CB Q35195457-2D6BA53E-5009-4D38-A676-F4C42E8E76FF Q35609674-4421CDF1-4FED-48C6-B424-9A4A6F63E76E Q35629109-F3D17183-A654-4437-B707-F7A2244E9530 Q35761403-F1250053-64A8-4D72-A6EF-0265B76AA1DA Q35790559-DEAFDE97-B8A8-4747-B88E-72F69E83B607 Q36120936-4BF09196-1FD5-436D-9707-9D5A4A0F14DF Q36144377-5B1418F5-CAA9-4DCF-87D3-20B4088F826B Q36645826-29488D03-7538-49AF-991E-5E2F9BDBAEBA Q36715466-D161B142-9523-435C-B689-AC1CD4C4F341 Q36762423-E6554134-8A93-4EEB-BAB1-38AC9C075E13 Q36986634-116A4DE5-B6F2-4F5D-830D-36D126FF87BE Q37143102-64752C31-6767-4150-A12C-1279B87157CF Q37149572-2B2079D0-6DEA-4796-96DA-EBB7171E7868 Q37223156-A1657683-F325-4010-946D-497E60993449 Q37317444-FFC2A585-B323-4817-BBBD-B0C5FEB076C5 Q37587217-FFD6B1FA-891A-4917-A463-8D16123D3A31 Q37682512-8CD2AB1F-4AFB-4600-914E-5FFDCB9FBCFF Q37727232-17E54774-7E10-4ED4-BE49-F79CA6ECA884 Q37789000-F6F50658-3C37-484A-BEBE-91823E051874 Q37827164-C30E50E5-E358-4572-9A7A-7A9A8CF579B2 Q37870151-E2809D5E-702A-4818-A17D-32CF8E35B65C Q38056892-8736347D-5119-4E2D-8289-8DF68EE13D6B Q38293796-BCDD790E-69CE-45AB-BA6F-1DFBE1272794 Q38418160-108CFA3D-D84B-44D0-8C95-9BC4E7D07232

P2860

Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines.

http://www.wikidata.org/entity/Q35595076

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

2002年论文

@zh

2002年论文

@zh-cn

name

Sulphasalazine and mesalazine: ...... mittee on Safety of Medicines.

@ast

Sulphasalazine and mesalazine: ...... mittee on Safety of Medicines.

@en

type

label

Sulphasalazine and mesalazine: ...... mittee on Safety of Medicines.

@ast

Sulphasalazine and mesalazine: ...... mittee on Safety of Medicines.

@en

prefLabel

Sulphasalazine and mesalazine: ...... mittee on Safety of Medicines.

@ast

Sulphasalazine and mesalazine: ...... mittee on Safety of Medicines.

@en

P1433

Q35595076-4694D184-ED58-4A39-8448-77DCBB633A67

P1476

Q35595076-8DE89CD7-8696-433D-A34D-A24F073954A8

P2093

Q35595076-AA55DB0C-B9E0-48E6-A08B-AC00F8CBF945

Q35595076-B3389AF1-DB42-4B7B-9AF4-27196A1975D1

P2860

Q35595076-0449EA67-BF29-4668-A09F-33C22D6C3799

Q35595076-098BED17-1A14-47A0-9ADC-1F581CE441AC

Q35595076-1D2CA6A6-0F3C-40C8-A927-A769184A06AF

Q35595076-2C2AB11D-9AB0-4ECC-9A43-72185626B9CA

Q35595076-35CDE269-A0A0-4367-A190-B21A0DFC1C75

Q35595076-3B59597B-584F-4E2C-B79C-C51A69BF256E

Q35595076-49AEBF15-E96C-431D-B05F-B8843C3B782F

Q35595076-60638006-FCC8-4F77-A7A3-0424E1146C2C

Q35595076-66BB90B1-34DA-4F23-A984-D93BC405DB5A

Q35595076-8272CE4D-323C-4AAA-8D53-A6DA33FB6ABE

P304

Q35595076-FFBBBDF9-F4BC-4790-828D-38D32523AD71

P31

Q35595076-6F31AEE7-75DE-447A-86B3-48FBCCFBBA5C

P356

Q35595076-6BF11215-A37C-4FE3-B9A8-C6E814C5F212

P407

Q35595076-34DEE8C6-31F8-4503-A1FF-DDC855938DF0

P433

Q35595076-D3233434-D38B-4B30-821C-22B4D1C0EEED

P478

Q35595076-6162EEBC-F6B2-4D3B-8976-8E2D763325E1

P577

Q35595076-A2361BAE-12DB-4716-B853-1933CED04617

P5875

Q35595076-3FDF29CF-EBFA-45AF-9F33-9659F065DB04

P698

Q35595076-2F0D37A7-6360-4AF4-B97F-57BA3B9780EE

P932

Q35595076-E2E712FF-1D06-43E4-9162-2BDEE6D8E2A7

P356

P1433

P1476

Sulphasalazine and mesalazine: ...... mittee on Safety of Medicines.

@en

P2093

M J S Langman

http://www.w3.org/2001/XMLSchema#string

R A J Ransford

http://www.w3.org/2001/XMLSchema#string

P2860

Ulcer complications associated with anti-inflammatory drug use. What is the extent of the disease burden?

Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype

Successfully treated sulphasalazine-induced fulminant hepatic failure, thrombocytopenia and erythroid hypoplasia with intravenous immunoglobulin.

Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate

Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease.

Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion

Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse

Direct toxicity of nonsteroidal antiinflammatory drugs for renal medullary cells.

Hypersensitivity to salicylazosulfapyridine: renal and hepatic toxic reactions.

An experiment to determine the active therapeutic moiety of sulphasalazine.

P304

536-539

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUT.51.4.536

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P577

2002-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11155760

http://www.w3.org/2001/XMLSchema#string

P698

12235076

http://www.w3.org/2001/XMLSchema#string

P932

1773410

http://www.w3.org/2001/XMLSchema#string